Published in N Engl J Med on October 23, 2003
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J (2005) 1.59
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. Eur Urol (2013) 1.54
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer (2005) 1.48
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Bone matters in lung cancer. Ann Oncol (2012) 1.08
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging (2012) 0.98
Bone health and prostate cancer. Prostate Cancer Prostatic Dis (2009) 0.97
Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer (2006) 0.93
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol (2012) 0.89
The SAPHO syndrome revisited with an emphasis on spinal manifestations. Skeletal Radiol (2014) 0.89
Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol (2014) 0.89
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption. Osteoporos Int (2009) 0.89
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol (2008) 0.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer (2013) 0.86
Side effects of bone-targeted therapies in advanced breast cancer. Breast Care (Basel) (2014) 0.86
Bisphophonates in CKD patients with low bone mineral density. ScientificWorldJournal (2013) 0.84
Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer (2008) 0.84
Thrombotic thrombocytopenic purpura following zoledronic acid infusion with a fatal outcome. BMJ Case Rep (2009) 0.83
Bisphosphonates in children with hypercalciuria and reduced bone mineral density. Pediatr Nephrol (2008) 0.82
Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B. J Bone Miner Metab (2012) 0.81
Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. J Cardiovasc Electrophysiol (2015) 0.79
Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. Rheumatol Int (2014) 0.79
Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag (2007) 0.78
A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone. Sci Rep (2016) 0.78
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials (2015) 0.78
Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol (2006) 0.78
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study. Support Care Cancer (2010) 0.78
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer (2004) 0.78
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. Osteoporos Int (2008) 0.77
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol (2008) 0.77
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway. Int J Mol Sci (2015) 0.75
Severe polyarthritis secondary to zolendronic acid: a case report and literature review. Clin Cases Miner Bone Metab (2015) 0.75
Lenalidomide-induced acute interstitial nephritis. Oncologist (2010) 0.75
Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag (2008) 0.75
Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis. Contemp Oncol (Pozn) (2012) 0.75
Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Miner Bone Metab (2016) 0.75
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol (2016) 0.75
Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates. Pediatr Nephrol (2008) 0.75
Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med (2002) 3.82
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 3.20
Sodium phosphate tablets and acute phosphate nephropathy. Am J Gastroenterol (2009) 2.80
Pregnancy and pregnancy rates in association with isotretinoin (Accutane). J Am Acad Dermatol (2002) 2.23
Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med (2005) 1.99
Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf (2004) 1.57
Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol (2002) 1.55
Troglitazone-induced liver failure: a case study. Am J Med (2003) 1.15
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr (2009) 1.14
Uterine sarcoma associated with tamoxifen use. N Engl J Med (2002) 1.11
Aseptic meningitis associated with rofecoxib. Arch Intern Med (2002) 1.10
Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign. Pharmacoepidemiol Drug Saf (2003) 0.97
Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med (2002) 0.97
Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage (2010) 0.97
Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf (2002) 0.94
Changes in ciprofloxacin utilization as shown in a large pharmacy claims database: effects of proximity to criminal anthrax exposure in October 2001. J Am Pharm Assoc (2003) (2003) 0.92
FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder. N Engl J Med (2015) 0.90
Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry (2002) 0.86
Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol (2002) 0.85
Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. Clin Pharmacol Ther (2002) 0.82
Clozapine and venous thromboembolism. Am J Psychiatry (2002) 0.78
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging (2004) 0.78
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 0.75
U.S. Food and drug administration analysis of strokes associated with raloxifene. Obstet Gynecol (2007) 0.75